Our Products
Loans
Cards
Insurance
Investment
Stock Market
Electronics Mall
CIBIL Score
Knowledge Centre
Academy 
Calculators
Our Services
Cibil Report
Get cibil report
My Account
Log In
Log into your account
Offers
Check out pre-approved offers now!
Languages
Chosen Language: English
Do Not Call
Do not call
En
Par Drugs And Chemicals Ltd. Share Price
N/A
1D
1M
3M
6M
1Y
5Y
Day's Range
Day's Range
Low
₹93.21
High
₹96.99
Price Summary
| Previous Close | ₹93.79 |
|---|---|
| Day's Range | ₹93.21 - ₹96.99 |
| Open | ₹96.31 |
| 52 Week Range | ₹78.05 - ₹122.43 |
| Volume | 12,063 |
| Market Cap | ₹0.00 |
Stocks Summary
| Trade Value ( ₹ in Lacs) | 11.31 |
|---|---|
| Market Cap (₹ in Mn) | 0.00 |
| Dividend Yield(%) | 0.00 |
| Price/Earning (TTM) | 9.03 |
| TTM EPS (₹) | 10.65 |
| P/E Ratio | 7.82 |
| Book Value(₹) | 1.06 |
| PAT Margin (%) | 11.78 |
| Face Value (₹) | 10.00 |
| ROCE(%) | 19.51 |
Financials
| Particulars | QTR FY (₹ in Millions) | Annual FY (₹ in Millions) |
|---|---|---|
| Net sales | 223.3 | 1009.74 |
| Expenses | N/A | N/A |
| PBT | 22.79 | 179.23 |
| Operating profit | 0.0 | 0.0 |
| Net profit | 16.51 | 133.58 |
About Par Drugs And Chemicals Ltd.
| Founded | 1999 |
|---|---|
| Managing Director | Falgun Vallabhbhai Savani |
| NSE Symbol | PAR |
Latest News
Jul
24
2026
Posted on Jul 24th 2026
Trident Lifeline submits board meeting intimation
Trident Lifeline has informed that pursuant to Regulation 29 of SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015, a meeting of the Board of Directors of the company will be held on Wednesday, July 29, 2026, to consider, approve and take on record the Unaudited Financial Results (Standalone & Consolidated) of the Company for the quarter ended 30th June, 2026; and any other items with the permission of the chairman. Further, Pursuant to the provisions of SEBI (Prohibition of Insider Trading) Regulations, 2015, as amended, read with Code of Conduct framed by the Company and in continuation to letter dated June 27, 2026 the Trading Window for trading in the Company’s equity shares was closed from 01st July 2026 and shall reopen 48 hours after the results of the meeting are made public on July 29, 2026.
The above information is a part of company’s filings submitted to BSE.
Read More
Jul
24
2026
Posted on Jul 24th 2026
Panacea Biotec informs about disclosure
Pursuant to Regulation 30 read with Para B of Part A of Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (‘SEBI LODR Regulations’), Panacea Biotec has informed that the Company’s wholly owned subsidiary, Panacea Biotec Pharma (‘PBPL’), has received a Show Cause Notice dated July 23, 2026, from the office of the Assistant Commissioner, Goods and Services Tax (‘GST’), Delhi under Section 73 of Delhi Goods & Services Tax / Central Goods & Services Tax Act & Rules, 2017 alleging total tax liability of ₹4.06 Crore including interest, tax and penalty, on account of alleged excess claim of Input Tax Credit in the Annual Return filed for the Financial Year 2022-23. The requisite details as required under Regulation 30 of the SEBI LODR Regulations read with SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026, and Industry Standards on Regulation 30 of SEBI LODR Regulations, are annexed as Annexure A.
The above information is a part of company’s filings submitted to BSE.
Read More
Jul
24
2026
Posted on Jul 24th 2026
Divi's Laboratories informs about earnings call
Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, Divi's Laboratories has informed that it enclosed the schedule of earnings conference call for the quarter ended June 30, 2026, to be held on August 01, 2026.
The above information is a part of company’s filings submitted to BSE.
Read More
Jul
24
2026
Posted on Jul 24th 2026
Sun Pharmaceutical Industries informs about press release
Sun Pharmaceutical Industries has informed that it enclosed a copy of the press release titled ‘Sun Pharma Notes Organon Shareholder Approval for Proposed Acquisition,’ which shall be released after this intimation.
The above information is a part of company’s filings submitted to BSE.
Read More
Jul
24
2026
Posted on Jul 24th 2026
Cipla - Quaterly Results
The company's total revenue for the quarter ended June 2026 saw a slight change in the total revenue, having registered a total revenue of Rs. 50776.80 millions.Net profit of the cmpany stood at Rs. 8621.60 millions for the quarter ended June 2026 a decline of -33.84% from Rs. 13031.30 millions in the same quarter last year.Operating Profit reported a sharp decline to 13286.90 millions from 18955.20 millions in the corresponding previous quarter.
| (Rs. in Million) |
| Quarter ended | Year to Date | Year ended | |||||||
| 202606 | 202506 | % Var | 202606 | 202506 | % Var | 202603 | 202503 | % Var | |
| Sales | 50776.80 | 50461.70 | 0.62 | 50776.80 | 50461.70 | 0.62 | 189799.50 | 190448.50 | -0.34 |
| Other Income | 2427.50 | 2710.70 | -10.45 | 2427.50 | 2710.70 | -10.45 | 11226.50 | 9847.20 | 14.01 |
| PBIDT | 13286.90 | 18955.20 | -29.90 | 13286.90 | 18955.20 | -29.90 | 55890.40 | 67631.60 | -17.36 |
| Interest | 56.80 | 58.80 | -3.40 | 56.80 | 58.80 | -3.40 | 193.00 | 151.10 | 27.73 |
| PBDT | 13230.10 | 18896.40 | -29.99 | 13230.10 | 18896.40 | -29.99 | 53253.70 | 70427.10 | -24.38 |
| Depreciation | 1693.90 | 1456.90 | 16.27 | 1693.90 | 1456.90 | 16.27 | 6894.30 | 5738.90 | 20.13 |
| PBT | 11536.20 | 17439.50 | -33.85 | 11536.20 | 17439.50 | -33.85 | 46359.40 | 64688.20 | -28.33 |
| TAX | 2914.60 | 4408.20 | -33.88 | 2914.60 | 4408.20 | -33.88 | 11207.60 | 13111.70 | -14.52 |
| Deferred Tax | -164.30 | -152.20 | 7.95 | -164.30 | -152.20 | 7.95 | 188.60 | -491.50 | -138.37 |
| PAT | 8621.60 | 13031.30 | -33.84 | 8621.60 | 13031.30 | -33.84 | 35151.80 | 51576.50 | -31.85 |
| Equity | 1615.70 | 1615.50 | 0.01 | 1615.70 | 1615.50 | 0.01 | 1615.60 | 1615.20 | 0.02 |
| PBIDTM(%) | 26.17 | 37.56 | -30.34 | 26.17 | 37.56 | -30.34 | 29.45 | 35.51 | -17.08 |
Read More
No Records Found
Sign in to Unlock Offers!
We don't SPAM
Frequently Asked Questions
The current share price of is ₹ as of .
The market capitalisation of is ₹ as of .
The 1-year return of is % as of .
The P/E ratio of is as of .
The 52-week high and low of are ₹ and ₹, respectively, as of .
View More
Disclaimer
All content and research information displayed on the Site, are obtained from our partner Accord Fintech Private Limited. an authorized data feed vendor of BSE/NSE/MCX/NCDEX exchange. The data is provided on ‘As-Is’ basis and is not a live data feed but a feed with 15 minutes delay or more. Bajaj Markets does not warrant accuracy, completeness, timely availability of the information and data available on the Site. Past performance, when presented, is purely for reference purposes and is not a guarantee of similar future results.
The Services offered on the Site does not constitute investment advice in any manner whatsoever. You shall be solely responsible for any investment decisions made by placing reliance on the information provided on the Site.
Bajaj Markets partners with financial services entities for sourcing leads for services such as DEMAT accounts etc. In case you wish to avail the services, you shall be redirected to partners platform and shall be bound by the terms and conditions, privacy policy governing the said platform.
Home
Shopping
Loan Offers
My Accounts
Explore
